[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100109423":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":11,"locations":37,"responsibleParty":49,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":80,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL",null,[13],"Drug: AZD8848",{"label":15,"type":16,"description":11,"interventionNames":17},"2","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","AZD8848","Concentrate for nasal spray,solution 60 mg\u002Fg",[9],{"type":21,"name":26,"description":11,"armGroupLabels":27,"otherNames":11},"Placebo",[15],[29,33],{"name":30,"affiliation":31,"role":32},"Edward Högestätt","Department of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine on University Hospital Lund, Sweden","PRINCIPAL_INVESTIGATOR",{"name":34,"affiliation":35,"role":36},"Leif T Eriksson","AstraZeneca R&D, Lund","STUDY_DIRECTOR",[38],{"facility":39,"status":11,"city":40,"state":11,"zip":11,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":11},"Research Site","Lund","Sweden","SE",{"type":44,"coordinates":45},"Point",[46,47],13.19321,55.70584,{"lat":47,"lon":46},{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100109423","phase-1-tolerabilitysafety-of-intranasal-azd8848-in-healthy-male-volunteers-and-seasonal-allergic-rhinitis-male-patients-out-of-season-100109423",false,"NCT00688779","Tolerability\u002FSafety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season","A Double Blind, Placebo Controlled, Randomised, First Time In Man. Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD8848 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out Of Season","SAD","Inclusion Criteria:\n\n* History of birch and\u002For timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years\n* Body mass index (BMI) between 19 and 30 kg\u002F m2 and a weight between 50 and 100 kg\n* No clinically relevant abnormal findings\n\nExclusion Criteria:\n\n* Acute illness which requires medical intervention\n* Definite or suspected personal history of adverse drug reactions or drug hypersensitivity\n* Clinical relevant disease or disorder (past or present)\n* A history of asthma",true,"MALE","18 Years","45 Years",{"count":64,"type":65},130,"ACTUAL","INTERVENTIONAL",[68],"PHASE1","Investigate safety\u002Ftolerability after a single dose intranasal administration of AZD8848 comparator placebo to healthy male volunteers and seasonal allergic rhinitis male patients out of season",[71,72],"Healthy","Allergic Rhinitis",[74,75,76,77,78,79],"Healthy male","allergic rhinitis","tolerability","safety","intranasally","Healthy subjects","COMPLETED","2015-08-13",{"date":83,"type":84},"2015-08-14","ESTIMATED",{"date":86,"type":11},"2008-01",{"date":88,"type":65},"2009-04",{"name":5,"class":6},1]